phase genesi studi get earli nod dmc reiter
report updat clinic program adjust target
price increas share outstand
analyst certif import disclosur see
mdwd announc net revenu line consensu estim eu nexobrid sale mdwd report gaap ep
vs estim consensu mdwd appear suffici fund cash june expect
burn develop nexobrid escharex nexobrid launch south korea mdwd complet enrol
nexobrid detect studi eschar remov top-lin data previous guid expect mdwd file bla
nexobrid cid studi pediatr patient expand us first patient treat look forward
updat strateg discuss
phase genesi studi get earli nod dmc reiter outperform
tuesday biolinerx announc posit result lead-in cohort genesi compani phase trial investig
stem cell mobil patient undergo autolog transplant data prompt data monitor committe dmc recommend
move forward random segment studi slate enrol patient remind lead-in cohort conduct
test safeti efficaci slightli higher dose mg/kg previous test transplant patient importantli
optim cell yield collect patient reinforc belief genesi could hit primari endpoint manag
indic genesi remain track deliv top line result reiter outperform rate pt
report updat clinic program adjust target price increas share outstand
loss per share compar estim loss result lower estim oper expens sg
million lower estim million million lower estim million
addit share outstand higher estim revenu outlook remain unchang reduc
estim oper expens driven reduct estim sg outlook oper expens
remain unchang
core ep one-tim tcja benefit compar estim consensu
year-over-year vs adj last year segment om rose bp y-o-i edg estim revenu rose
y-o-i core net a/d fx vs estim organ slightli estimate autom solut om bp vs
estim organ growth organ revenu guidanc rais autom solut
 rais ep guidanc new guidanc reflect core basi
excl tcja excl item acquisit charg one-tim employe contribut compar
vs in-lin
